SLC5A2 and type 2 diabetes mellitus: Similarly, a study by Tahara et al. in a T2D murine model has shown a comparable increase in urinary glucose excretion and a reduction in blood glucose levels with DAPA when compared to the other SGLT2 inhibitors EMPA and CANA, used in this study [21].